Coronavirus pneumonia. This code assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing
Conditions
Interventions
Intervention 1: Intervention group: In addition to the usual treatment regimen, patients receive captopril at a dose of one 25 mg tablet every 8 hours for 2 weeks from the start of treatment (Without
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: COVID-19 disease confirmed by imaging (HRCT) or Real Time PCR
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Bilateral renal artery stenosis Hereditary angioedema Psoriasis NSAID consumtion Patients who have been taking Captopril before undergoing Covid due to other underlying diseases (such as hypertension, heart failure, myocardial infarction, etc.) will not be included in the study. Patients in need of ICU admission The patient participates in any other clinical trial on the corpus associated with therapeutic intervention. (Before entering this study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of oxygen secretion. Timepoint: At the beginning of the study (before the intervention) and 14 days after the start of taking captopril. Method of measurement: Using a pulse oximeter.;Mortality rate. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report.;Duration of hospitalization. Timepoint: At the end of hospitalization of patients. Method of measurement: According to the physician report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMousalreza Hoseini
Mashhad University of Medical Sciences
Outcome results
None listed